Kazia Therapeutics Limited KZIA

NAS: KZIA | ISIN: US48669G1058 20/05/2024

0,275 USD (-2,55%)

(-2,55%) 20/05/2024

Grafiek Kazia Therapeutics Limited

Grafiek Kazia Therapeutics Limited

1 dag1d -2,55%
1 week1w -8,24%
1 maand1m -27,06%
3 maanden3m -30,71%
6 maanden6m -64,36%
1 jaar1j -78,00%
5 jaar5j -91,18%

Kazia Therapeutics Limited in het nieuws

Toon enkel gratis nieuws

1 mei 2024 · Kazia Reports Successful Stage 1 Completion Of The Evt801 Phase 1 Clinical Trial In Advanced Cancer Patients · Persbericht

21 maart 2024 · Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases · Persbericht

13 maart 2024 · Kazia announces presentation of new data at AACR Annual Meeting · Persbericht

21 februari 2024 · Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint · Persbericht

18 januari 2024 · Kazia Continues Board Renewal With Two New Appointments · Persbericht

6 december 2023 · Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering · Persbericht

1 december 2023 · Kazia Therapeutics Announces $2 Million Registered Direct Offering · Persbericht

10 november 2023 · Kazia Announces Publication In Molecular Cancer Therapeutics Highlighting Paxalisib Preclinical Data In Melanoma · Persbericht

1 november 2023 · Kazia Therapeutics Provides Preliminary Update From Ongoing Phase 2 Study Of Paxalisib In Primary Cns Lymphoma · Persbericht

23 oktober 2023 · Kazia Therapeutics Announces Clinical Data At Esmo 2023 From Ongoing Phase 1 Evt801 Study · Persbericht

Profiel Kazia Therapeutics Limited

Gezondheidstechnologie

Medicinale en botanische productie

Werknemers: 60

Aandelen Kazia Therapeutics Limited

Beurswaarde: 6,67 miljoen USD

Effecten: 23,63 miljoen

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe